Post-earnings recap
Reported
Tue, Apr 28, 2026
EPS actual
$1.99
EPS est.
$2.11
EPS surprise
-5.60%
1-day move
+0.91%
The earnings report indicates that Novartis is facing challenges in meeting earnings expectations, as reflected by the EPS miss. The stock's slight decline of 0.88% suggests that investors may be concerned about the company's short-term performance. Without revenue figures or updated guidance, uncertainty remains about future growth prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.99 | $2.07 | -5.60% |
| Revenue | N/A | $13.5B | N/A |
Management expressed a commitment to their product pipeline and innovation. They acknowledged current market challenges but remained cautiously optimistic about future prospects.
We are focused on maintaining our pipeline despite current challenges.
Our commitment to innovation remains strong as we navigate market dynamics.
Novartis AG (NVS) is a global healthcare company focused on developing and manufacturing pharmaceuticals. With a market cap of $275 billion, it plays a crucial role in the healthcare sector, addressing various medical needs through innovative treatments.
Last quarter
In Q4-2025, Novartis reported an EPS of $2.03, beating expectations by 2.11%. The stock reacted positively, gaining 2.04% the following day.
Management promises and guidance
EPS beat streak
1Q
EPS beat rate
75%
Avg EPS surprise
+4.23%
Avg 1-day reaction
-0.69%
Analysts expect Novartis to report steady earnings and revenue, with a consensus EPS of $2.07 and revenue of $13.5 billion. Investors are keen to see if the company can maintain its growth trajectory.
Bull case
If Novartis exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products and effective management strategies.
Bear case
Conversely, if the company misses earnings targets or provides weak guidance, it may raise concerns about its competitive position and market dynamics.
Key metrics to watch
EPS
$2.07Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue
$13.5BTotal revenue reflects the company's sales performance and market demand for its products, which is essential for growth.
The print will turn on these.
Q1
Will Novartis achieve an EPS of $2.07 or higher?
This figure is critical as it directly impacts investor confidence and stock performance.
Q2
What guidance will management provide for revenue growth?
Future revenue expectations will influence market sentiment and the company's growth outlook.
—
Est. EPS
$1.52
Est. Rev
$3.6B
Impl. Move
±39.2%
Why consensus could be wrong
The Street may underestimate Novartis' ability to innovate and capture market share, leading to potential upside in earnings.
Supporting evidence
The company has a history of beating EPS estimates, with an 88% success rate in the last eight quarters.
Options pricing suggests a larger move than historical averages, indicating potential for a surprise.
Recent positive developments in drug approvals could drive unexpected revenue growth.
Key risk
If Novartis reports an EPS below $2.00, it could challenge the optimistic growth narrative.
Pre-commit to what would confirm each case.
The market is closely watching how Novartis navigates competitive pressures and manages its product pipeline.
Bull confirmed if
An EPS of $2.10 or higher would confirm strong operational performance and investor confidence.
Bear confirmed if
An EPS below $2.00 would raise concerns about profitability and growth prospects.
What the market is pricing for the move.
Implied Move
±5.44%
Historical Avg
±2.3%
The options market is pricing in a significant move, indicating that investors anticipate volatility around the earnings report.
Options are pricing ±5.8% while NVS has averaged ±2.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
20.2%
Smart-money positioning from the most recent 13F filings.
Institutional
7.27%
of float
Insider
0.01%
of float
Holders
1,806
institutions
Top Holders· as of Jun 2026
Fisher Asset Management, LLC
15,523,378 sh · $2.2B
0.76%
11.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Novartis beats expectations, history suggests a potential average one-day move of +2.66%, confirming strong demand and operational efficiency.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors digest the details.
Miss
Should the company miss earnings expectations, history indicates an average one-day move of -4.42%, reflecting investor disappointment.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Morgan Stanley
8,726,827 sh · $1.3B
0.43%
2.3%
Dimensional Fund Advisors LP
8,117,586 sh · $1.2B
0.40%
0.1%
Primecap Management Company
6,592,124 sh · $944.5M
0.32%
-12.9%
LOOMIS SAYLES & CO L P
5,239,309 sh · $750.7M
0.26%
-3.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Aug 27, 2026 · disclosed Sep 25, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.